Filing Flows › Health Care › Tonix Pharmaceuticals Holding (TNXP)
Tonix Pharmaceuticals Holding (TNXP) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 10, 2026 · Tonix Pharmaceuticals Holding (TNXP) Q2 2026 earnings results →
Q2 2026 Revenue up 578% year over year to $13.5M · 299¢ of every $1 of revenue lost · operating margin -314.1%
Tonix Pharmaceuticals Holding made $13.5M in Q2 2026 (+578% Y/Y): Tonmya $11.0M, Zembrace Symtouch $2.0M, Tosymra $594K. Operating margin -314.1%, net loss $40.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 10, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $13.5M in Q2 2026, up 578% year over year and up 97% from the previous quarter. Tonmya was the largest line at 81% of revenue. Zembrace Symtouch added $426K year over year (up 27%), 4% of the total change.
Operating costs exceeded revenue by $42.5M, an operating margin of -314.1%. Total costs grew 85% against revenue growth of 578%. The fastest-growing cost line was SG&A (+122%). The quarter ended with a net loss of $40.6M, wider than the previous quarter's $40.2M loss.
Operating cash flow was −$42.2M. Non-cash charges added back $619K of depreciation and amortization and $2.3M of share-based compensation. Working capital and other items used $4.6M. Capital expenditures of $587K exceeded it, leaving free cash flow of −$42.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 10, 2026 | $13.5M | +578% | -314.1% | −$40.6M | −$42.2M |
| Q1 2026 | 10-Q | May 11, 2026 | $6.9M | +183% | -603.9% | −$40.2M | −$42.3M |
| Q4 2025 | 10-K | Mar 12, 2026 | $5.4M | +109% | -895.8% | −$46.9M | −$39.6M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $3.3M | +17% | n/m | −$32.0M | −$28.8M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $2.0M | -10% | n/m | −$28.3M | −$14.8M |
| Q1 2025 | 10-Q | May 12, 2025 | $2.4M | -2% | -660.9% | −$16.8M | −$16.6M |
| Q4 2024 | 10-K | Mar 18, 2025 | $2.6M | -32% | -870.6% | −$22.1M | −$14.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Tonix Pharmaceuticals Holding
Tonix Pharmaceuticals (“Tonix” or the “Company”) is a fully-integrated biopharmaceutical company commercializing and developing innovative therapies for central nervous system (“CNS”) disorders, infectious diseases, immunology, and rare diseases. Our portfolio consists of both commercial and development-stage programs. Tonix markets TONMYA® (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults in the U.S., as well as Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) for the treatment of acute migraine in adults in the U.S. Tonix received approval from the U.S. Food and Drug Administration (“FDA”) for TONMYA for the treatment of fibromyalgia in August 2025 and commercially launched TONMYA in November 2025.
In its own words, from its 10-Q, filed Aug 10, 2026.
Tonix Pharmaceuticals Holding against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +578% against the peers' median +10%. Operating margin: -314.1% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Q2 2026 | $13.5M | +578% | -314.1% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Tonix Pharmaceuticals Holding 10-Q on SEC EDGAR · CIK 1430306 · Pharmaceutical Preparations
13F: who owns TNXP and who is buying
More on TNXP
- How Tonix Pharmaceuticals Holding makes money: revenue by segment
- Tonix Pharmaceuticals Holding next earnings date and what analysts expect
- Tonix Pharmaceuticals Holding stock forecast, price target and fair value
- Who owns Tonix Pharmaceuticals Holding stock: holders, funds and Congress trades
- Tonix Pharmaceuticals Holding recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results